Corvus Pharmaceuticals, Inc. (CRVS): Total Assets
$71.12M
As of 2025-12-31
$239.27M
As of 2026-06-30
+1.4%
3-year compound annual growth
-3.6%
5-year compound annual growth
-3.2%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $71.12M | +3.2% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $68.91M | +51.3% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $45.55M | -33.2% | 2025-03-25, Balance as of period end |
| 2022-12-31 | $68.24M | -37.7% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $109.45M | +28.0% | 2023-03-28, Balance as of period end |
| 2020-12-31 | $85.53M | +2.3% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $83.65M | -29.3% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $118.23M | +24.8% | 2020-03-09, Balance as of period end |
| 2017-12-31 | $94.78M | -32.4% | 2019-03-07, Balance as of period end |
| 2016-12-31 | $140.15M | +42.3% | 2018-03-01, Balance as of period end |
| 2015-12-31 | $98.46M | n/a | 2017-03-10, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | $71.12M | +3.2% |
| Aldeyra Therapeutics, Inc. (ALDX) | 2025-12-31 | $72.06M | -31.1% |
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | $69.40M | -45.3% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $68.92M | -37.7% |
| Context Therapeutics Inc. (CNTX) | 2025-12-31 | $68.49M | -30.2% |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $74.31M | -34.4% |
| Grace Therapeutics, Inc. (GRCE) | 2026-03-31 | $66.65M | -7.4% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $76.82M | +1.6% |
| Adagene Inc. (ADAG) | 2025-12-31 | $78.26M | -12.3% |
Compare CRVS, ALDX, HOWL, SPRO side by side · Screen every company in Pharmaceutical Preparations ↗